Stock traders buy large volume of call options on Allakos (NASDAQ:ALLK)
Allakos Inc. (NASDAQ:ALLK – Get Rating) was the target of unusual options trading activity on Friday. Traders bought 4,335 call options on the stock. This is a 658% increase over the average volume of 572 call options.
Hedge funds weigh on Allakos
A number of institutional investors have recently increased or reduced their stake in ALLK. BlackRock Inc. increased its stake in Allakos shares by 8.4% in the first quarter. BlackRock Inc. now owns 2,911,899 shares of the company valued at $16,599,000 after purchasing an additional 226,498 shares last quarter. Goldman Sachs Group Inc. increased its stake in Allakos shares by 258.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,007,096 shares of the company worth $5,741,000 after acquiring 725,818 additional shares in the last quarter. DE Shaw & Co. Inc. increased its stake in Allakos shares by 5,817.1% in the fourth quarter. DE Shaw & Co. Inc. now owns 833,547 shares of the company worth $8,160,000 after purchasing an additional 819,460 shares during the period. Commodore Capital LP bought a new position in Allakos during Q4 worth $7,985,000. Finally, PDT Partners LLC increased its position in Allakos by 587.8% during the 1st quarter. PDT Partners LLC now owns 660,577 shares of the company valued at $3,765,000 after purchasing an additional 564,531 shares during the period. 66.67% of the shares are currently held by institutional investors and hedge funds.
Allakos price performance
ALLK stock was down $0.03 midday Friday, hitting $4.61. The company’s stock had a trading volume of 43,861 shares, compared to its average trading volume of 2,830,327. Allakos has a 12-month low of $2.54 and a 12-month high of 11.73 $. The company’s fifty-day moving average price is $3.80 and its 200-day moving average price is $4.14. The stock has a market capitalization of $252.81 million, a P/E ratio of -0.56 and a beta of 0.66.
Allakos (NASDAQ:ALLK – Get Rating) last released its quarterly earnings data on Thursday, August 4. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analyst consensus estimates of ($0.86) by ($0.04). Equity analysts expect Allakos to post an EPS of -6.01 for the current financial year.
Allakos Company Profile
(Get a rating)
Allakos Inc, a clinical-stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergic, inflammatory and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a phase II/III study for eosinophilic esophagitis; and a phase II clinical study in atopic dermatitis and chronic spontaneous urticaria.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Allakos, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Allakos wasn’t on the list.
While Allakos currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here